Drug intelligence / Profile preview

alpinumisoflavone

Development stage
Preclinical
Modality
Small Molecules
Administration
Oral, Topical
01

Overview

Alpinumisoflavone is a **prenylated isoflavonoid** natural product isolated mainly from the unripe fruits of *Maclura tricuspidata* and also found in *Maclura pomifera* and *Ficus nervosa*. It exhibits a broad spectrum of preclinical pharmacological activities, including **anti-inflammatory**, **antioxidant**, **antimetastatic**, **antimicrobial**, **anticancer**, **antiangiogenic**, **estrogenic/antiestrogenic**, **antiosteoporotic**, **antidiabetic**, and **neuroprotective** effects[4][7][1]. Mechanistic studies indicate that alpinumisoflavone inhibits the expression of vascular endothelial growth factor (VEGF), fibrotic markers (alpha-SMA, collagen I), and pro-angiogenic signaling proteins (MMP-9, VEGFR-2, RET, HER2, EGFR, FGFR4) in cell and animal models. It has demonstrated safety and tolerability in animal studies at oral doses up to 100 mg/kg/day, and theoretical drug-likeness for oral or topical administration is high according to several rule-based drugability filters (Lipinski, Veber, Ghose, Egan, Muegge)[6]. No clinical trial, approved pharmaceutical formulation, or developer company is presently documented in public records.

Other names
Alpinum Isoflavone5-hydroxy-7-(4-hydroxyphenyl)-2,2-dimethylpyrano[3,2-g]chromen-6-one34086-50-55-hydroxy-7-(4-hydroxyphenyl)-2,2-dimethyl-2H,6H-benzo[1,2-b:5,4-b']dipyran-6-one
02

Targets

EGFR (Epidermal growth factor receptor)FGFR4 (Fibroblast growth factor receptor 4)ERBB2 (Erb-b2 receptor tyrosine kinase 2)MMP9 (Matrix metalloproteinase-9)RET (Rearranged during transfection receptor tyrosine kinase)VEGFR2 (Vascular endothelial growth factor receptor 2)

Beyond the preview

Go deeper on alpinumisoflavone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on alpinumisoflavone.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call